TNYA
Tenaya TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that the May 15, 2026 RIDGE-1 update and the still-pending first-half 2026 TN-201 follow-up extend the early clinical signal package and improve visibility toward 2026 regulatory-path discussions, while the Alnylam collaboration adds longer-horizon strategic optionality and external validation to Tenaya’s target-discovery platform [#PR-2026-03-05].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Even with cash expected to fund at least the next twelve months from the March 11, 2026 filing date, future financing and dilution risk remain material for a low-cap clinical-stage biotech [#10-K-2026-03-11].
Momentum
92
Value
41
Sentiment
31
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.65 · Bull $1.25 · Bear $0.30
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $9.14
Why
Momentum92 · Δ7d -
Value41 · Δ7d -0.1
Sentiment31 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
92
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
31
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 92.1 / Value 41.1 / Sentiment 31.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$177.29M
Beta
3.19
Shares Out
217M
P/E (TTM) · Derived
-1.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.26
Rev YoY
-
EPS YoY
-63.6%
Gross Margin
-3250.2%
Op Margin
-
Net Debt
-$89.72M
Current Ratio
5.75
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology